Following our observations, we explored whether the sensitivity of BRAF class 3–mutated NSCLC cell lines was limited to the first-generation EGFR-TKI or could be extended to osimertinib, a third-generation EGFR-TKI currently representing the standard of care for patients with EGFR-mutated NSCLCs. This evidence concerns the gene BRAF and non-small cell lung carcinoma.